Keros Therapeutics (KROS) Change in Cash (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Change in Cash data on file, last reported at -$406.1 million in Q4 2025.

• Quarterly Change in Cash fell 1488.37% year-over-year to -$406.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$272.5 million (down 218.99% YoY) and the FY2025 annual result came in at -$272.5 million, down 218.99% from the prior year.
• Change in Cash eased to -$406.1 million in Q4 2025, from $3.3 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $160.6 million in Q1 2025 to a low of -$406.1 million in Q4 2025.
• A 5-year average of $1.1 million and a median of $900500.0 in 2022 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash jumped 5071.22% — and 2025, when it slumped 1488.37%.
• Tracing KROS's Change in Cash over 5 years: stood at $8.7 million in 2021, then surged by 355.84% to $39.6 million in 2022, then grew by 9.17% to $43.3 million in 2023, then plunged by 32.38% to $29.2 million in 2024, then tumbled by 1488.37% to -$406.1 million in 2025.
• The last three Change in Cash figures came in at -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025), per Business Quant data.